Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial
Open Access
- 29 October 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-11
Abstract
Hepatocellular carcinoma (HCC) patients with macrovascular invasion (MVI) have dismal prognosis and there are no standard perioperative therapies. This phase 2 trial (ChiCTR2000036385) aimed to investigate the activity and safety of perioperative tislelizumab plus intensity modulated radiotherapy (IMRT) for resectable HCC with MVI. Thirty treatment-naïve patients with MVI received 3 cycles of tislelizumab intravenously (200 mg, every three weeks) and concurrent IMRT (45 Gray in 15 fractions). Primary endpoints were the overall response rate (ORR) and overall survival (OS). Secondary endpoints were the proportion of patients with a complete or major pathological response (pCR or MPR), recurrence-free survival (RFS) and safety. Of patients enrolled, 15 (50%) underwent curative surgery followed by adjuvant tislelizumab. The ORR was 30.0% (90% CI 16.6%-46.5%) and the median OS was 18.7 months. Of the 15 patients underwent surgical resection, 10 (66.7%) achieved pCR or MPR and 8 (53.3%) remained recurrence-free. The median RFS were not reached with a median follow-up of 21.77 months (95% CI 12.50-31.03) post-surgery. 4 (13.3%) patients experienced grade 3 treatment-related adverse events. The most common events were thrombocytopenia, leukopenia, and anemia. The trial has met the pre-specified endpoints, and these results support further studies of perioperative immunotherapy plus radiotherapy in HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81972777, 82373300, 81972810, and 82272999.)
This publication has 70 references indexed in Scilit:
- Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular CarcinomaJAMA Oncology, 2023
- Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular CarcinomaJAMA Surgery, 2022
- Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung CancerJAMA Oncology, 2021
- Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancerGastric Cancer, 2020
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2019
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functionsCancer Immunology, Immunotherapy, 2018
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 updateHepatology International, 2017
- Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) stagingJournal of Cancer Research and Clinical Oncology, 2012
- Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombusCancer, 2012
- The general rules for the clinical and pathological study of primary liver cancerSurgery Today, 1989